AR076512A1 - Formulacion en lipidos de un promotor de la apoptosis - Google Patents
Formulacion en lipidos de un promotor de la apoptosisInfo
- Publication number
- AR076512A1 AR076512A1 ARP100101470A ARP100101470A AR076512A1 AR 076512 A1 AR076512 A1 AR 076512A1 AR P100101470 A ARP100101470 A AR P100101470A AR P100101470 A ARP100101470 A AR P100101470A AR 076512 A1 AR076512 A1 AR 076512A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- prodrug
- salt
- disease
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Una composicion farmacéutica para administracion por vía oral, caracterizada porque comprende un sistema de droga-vehículo que comprende un compuesto de la formula (1) donde X3 es cloro o fluor; y (i) X4 es azepan-1-ilo, morfolin-4-ilo, 1,4-oxazepan-4-ilo, pirrolidin-1-ilo, N(CH3)2, N(CH3)(CH(CH3)2), 7-azabiciclo[2.2.1]heptan-1-ilo o 2-oxa-5-azabiciclo[2.2.1]hept-5-ilo; y R0 es un resto de formula (2), donde X5 es CH2, C(CH3)2 o CH2CH2; X6 y X7 son ambos hidrogeno o ambos metilo; y X8 es fluor, cloro, bromo o iodo; o (ii) X4 es azepan-1-ilo, morfolin-4-ilo, pirrolidin-1-ilo, N(CH3)(CH(CH3)2) o 7-azabiciclo[2.2.1]heptan-1-ilo; y R0 es un resto de formula (3), donde X6, X7 y X8 son como se definieron previamente; o (iii) X4 es morfolin-4-ilo o N(CH3)2; y R0 es un resto de formula (4), donde X8 es como se definio previamente; o una sal, prodroga, sal de una prodroga o un metabolito farmacéuticamente aceptable del mismo; en solucion en un vehículo sustancialmente no acuoso que comprende un componente de fosfolípido y un componente solubilizante farmacéuticamente aceptable; en donde dicho vehículo comprende entre cero y 25% en peso aproximadamente de etanol. Reivindicacion 7: La composicion de la reivindicacion 1, caracterizada porque el compuesto de la formula (1) es ABT-263 o una sal, prodroga, sal de una prodroga o un metabolito del mismo. Reivindicacion 20: Uso de una composicion de cualquiera de las reivindicaciones 1 - 19, caracterizado porque es para el tratamiento de una enfermedad caracterizada por una disfuncion apoptotica y/o sobreexpresion de una proteína anti-apoptotica de la familia Bcl-2, mediante la administracion por vía oral a un sujeto que sufre de la enfermedad de una cantidad terapéuticamente eficaz de la composicion. Reivindicacion 21: El uso de la reivindicacion 20, caracterizado porque la enfermedad es una enfermedad neoplásica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17424509P | 2009-04-30 | 2009-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076512A1 true AR076512A1 (es) | 2011-06-15 |
Family
ID=42732500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101470A AR076512A1 (es) | 2009-04-30 | 2010-04-30 | Formulacion en lipidos de un promotor de la apoptosis |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100280031A1 (es) |
| EP (1) | EP2424500A1 (es) |
| JP (1) | JP2012525434A (es) |
| KR (1) | KR20120013416A (es) |
| CN (1) | CN102458361A (es) |
| AR (1) | AR076512A1 (es) |
| AU (1) | AU2010242925A1 (es) |
| BR (1) | BRPI1014368A2 (es) |
| CA (1) | CA2758534A1 (es) |
| IL (1) | IL215473A0 (es) |
| MX (1) | MX2011011526A (es) |
| RU (1) | RU2011148518A (es) |
| SG (1) | SG175147A1 (es) |
| TW (1) | TW201043605A (es) |
| UY (1) | UY32600A (es) |
| WO (1) | WO2010127192A1 (es) |
| ZA (1) | ZA201107593B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI540132B (zh) | 2009-06-08 | 2016-07-01 | 亞培公司 | Ｂｃｌ-２族群抑制劑之口服醫藥劑型 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| JP6080312B2 (ja) | 2011-04-28 | 2017-02-15 | プラットフォーム ブライトワークス トゥー， リミテッド | 親油性医薬用薬剤の改良された非経口製剤ならびにそれを調製および使用するための方法 |
| CN102836160A (zh) * | 2012-10-10 | 2012-12-26 | 武汉大学 | 一种治疗癌症的组合药物 |
| TR201703149A2 (tr) * | 2017-03-01 | 2018-09-21 | Univ Yeditepe | Kemoterapi̇k i̇laç kompozi̇syonu |
| US11285159B2 (en) | 2019-11-05 | 2022-03-29 | Abbvie Inc. | Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
| IL111004A (en) * | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
| US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US5759548A (en) * | 1993-11-30 | 1998-06-02 | Lxr Biotechnology Inc. | Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
| US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US20020055631A1 (en) * | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| KR20030070150A (ko) * | 2001-01-31 | 2003-08-27 | 화이자 프로덕츠 인크. | Ｐｄｅ4 이소자임 억제제로서 유용한 에테르 유도체 |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| AU2006297853B2 (en) * | 2005-05-12 | 2010-08-19 | AbbVie Global Enterprises Ltd. | Apoptosis promoters |
| US20070104780A1 (en) * | 2005-10-25 | 2007-05-10 | Lipari John M | Formulation comprising a drug of low water solubility and method of use thereof |
| AU2008314647B2 (en) * | 2007-10-12 | 2013-03-21 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
| CN101939008A (zh) * | 2007-12-06 | 2011-01-05 | 雅培制药有限公司 | 用于治疗癌症的abt-263经口组合物 |
| US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US20100297194A1 (en) * | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US20100278921A1 (en) * | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| MX2011013797A (es) * | 2009-06-18 | 2012-01-30 | Abbott Lab | Suspension de farmaco estable de nanoparticula. |
| NZ598461A (en) * | 2009-09-20 | 2013-12-20 | Abbvie Inc | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases |
-
2010
- 2010-04-29 US US12/770,122 patent/US20100280031A1/en not_active Abandoned
- 2010-04-30 WO PCT/US2010/033074 patent/WO2010127192A1/en active Application Filing
- 2010-04-30 CN CN2010800296388A patent/CN102458361A/zh active Pending
- 2010-04-30 JP JP2012508758A patent/JP2012525434A/ja not_active Withdrawn
- 2010-04-30 AU AU2010242925A patent/AU2010242925A1/en not_active Abandoned
- 2010-04-30 CA CA2758534A patent/CA2758534A1/en not_active Abandoned
- 2010-04-30 MX MX2011011526A patent/MX2011011526A/es not_active Application Discontinuation
- 2010-04-30 EP EP10718372A patent/EP2424500A1/en not_active Withdrawn
- 2010-04-30 SG SG2011073640A patent/SG175147A1/en unknown
- 2010-04-30 KR KR1020117028612A patent/KR20120013416A/ko not_active Application Discontinuation
- 2010-04-30 TW TW099113988A patent/TW201043605A/zh unknown
- 2010-04-30 RU RU2011148518/15A patent/RU2011148518A/ru unknown
- 2010-04-30 BR BRPI1014368A patent/BRPI1014368A2/pt not_active IP Right Cessation
- 2010-04-30 UY UY0001032600A patent/UY32600A/es not_active Application Discontinuation
- 2010-04-30 AR ARP100101470A patent/AR076512A1/es not_active Application Discontinuation
-
2011
- 2011-10-02 IL IL215473A patent/IL215473A0/en unknown
- 2011-10-17 ZA ZA2011/07593A patent/ZA201107593B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010127192A1 (en) | 2010-11-04 |
| JP2012525434A (ja) | 2012-10-22 |
| MX2011011526A (es) | 2011-11-18 |
| AU2010242925A1 (en) | 2011-11-10 |
| US20100280031A1 (en) | 2010-11-04 |
| CA2758534A1 (en) | 2010-11-04 |
| BRPI1014368A2 (pt) | 2016-04-05 |
| CN102458361A (zh) | 2012-05-16 |
| ZA201107593B (en) | 2012-06-27 |
| UY32600A (es) | 2010-12-31 |
| EP2424500A1 (en) | 2012-03-07 |
| RU2011148518A (ru) | 2013-06-10 |
| KR20120013416A (ko) | 2012-02-14 |
| SG175147A1 (en) | 2011-11-28 |
| IL215473A0 (en) | 2011-12-29 |
| TW201043605A (en) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076512A1 (es) | Formulacion en lipidos de un promotor de la apoptosis | |
| AR076511A1 (es) | Composicion farmaceutica en lipidos estabilizada de un promotor de la apoptosis. uso. | |
| AR076514A1 (es) | Composicion farmaceutica para la administracion oral de un promotor de apoptosis. uso. | |
| ES2638074T3 (es) | Carbamatos para utilizar en el síndrome de piernas inquietas | |
| SV2011003912A (es) | Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| UY35586A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| BRPI0607860A2 (pt) | composição farmacêutica para o tratamento ou prevenção de doenças envolvendo obesidade, diabetes, sìndrome metabólica, doenças neuro--degenerativas e doenças de disfunção da mitocÈndria | |
| AR077464A1 (es) | Terapia de combinacion para el tratamiento de la diabetes | |
| AR070561A1 (es) | Anillos intravaginales monoliticos que comprenden progesterona y metodos para su fabricacion y uso | |
| UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
| AR087744A1 (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa | |
| AR062392A1 (es) | Uso de compuestos y derivados de 2,5 dihidroxibenceno para el tratamiento de rosacea | |
| ECSP067044A (es) | Compuestos para el tratamiento de trastornos inflamatorios | |
| UY29823A1 (es) | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones | |
| AR070367A1 (es) | Formulaciones de flibanserina | |
| JP2019513762A (ja) | 胆汁うっ滞及び線維症の処置方法 | |
| JP2023537840A (ja) | ナビロンを単独及びカンナビノイドと併用する経皮製剤 | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| AU2020203316A1 (en) | Novel regimes of FXR agonists | |
| ES2449237T3 (es) | Derivados de NDGA modificados por un puente de butano tetra-O-sustituidos, su síntesis y uso farmacéutico | |
| UY26720A1 (es) | Derivados del pirrol | |
| JP2016523830A5 (es) | ||
| EP3863640A1 (en) | Treatment of pruritus with p2x3 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |